Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS
Precigen Inc. (NASDAQ:PGEN) is one of the hot stocks to buy with huge upside potential.
Precigen Inc. (PGEN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Iridian Asset Management David Cohen And Harold Levy | 3,666,946 | $12,064,252 | -15% | 4.75% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.40 | 2,000 | $6,800.00 | 405,959 | 2025-09-26 | Filing | |
| $3.58 | 6,000 | $21,480.00 | 65,031 | 2025-09-29 | Filing | |
| $3.42 | 2,932 | $10,027.44 | 468,626 | 2025-09-26 | Filing | |
| $3.62 | 8,284 | $29,988.08 | 465,694 | 2025-09-25 | Filing | |
| $4.60 | 15,000 | $69,000.00 | 217,841 | 2025-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.38 | 106,837 | $361,109.06 | 346,070 | 2025-09-30 | Filing | |
| $3.60 | 67,523 | $243,082.80 | 452,907 | 2025-09-29 | Filing | |
| $3.41 | 1,809,667 | $6,170,964.47 | 14,597,161 | 2025-09-30 | Filing | |
| $3.68 | 3,596,892 | $13,236,562.56 | 8,520,537 | 2025-09-19 | Filing | |
| $3.86 | 1,403,360 | $5,416,969.60 | 12,117,429 | 2025-09-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 134,226 | $441,604 | 0.04% | |
| 2. | 28,985 | $101,158 | 0% | |
| 3. | 28,231 | $92,880 | 0% | |
| 4. | 20,000 | $65,800 | 0.04% | |
| 5. | 18,795 | $61,835 | 0% |
News See All
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization
Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company developing precision genetic medicines for oncology, infectious diseases, and rare conditions.
15 Best Biotech Penny Stocks to Invest in Right Now
Jared Holz, the healthcare strategist for Mizuho, spoke on CNBC's "Closing Bell Overtime" in July on whether the biotech industry is ready for a breakthrough.
Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization
Precigen, Inc. (NASDAQ:PGEN) is one of the best healthcare penny stocks to buy now.
11 Best Healthcare Penny Stocks to Buy Now
The US healthcare sector is one of the biggest in the world, with spending expected to reach $5.3 trillion this year.
Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS
Precigen, Inc. (NASDAQ:PGEN) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 3, Precigen, Inc.
12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds
On September 12, Franklin Templeton released its research on active U.S. small-cap management.
Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism
Precigen Inc. (NASDAQ:PGEN) is one of the best multibagger stocks to invest in right now.
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Hedge Fund Resource Center Billionaire Hedge Funds
